Source: Eur Respir J, 50 (2) 1700889; 10.1183/13993003.00889-2017
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Athénaïs Boucly, Jason Weatherald, Laurent Savale, Xavier Jaïs, Vincent Cottin, Grégoire Prevot, François Picard, Pascal de Groote, Mitja Jevnikar, Emmanuel Bergot, Ari Chaouat, Céline Chabanne, Arnaud Bourdin, Florence Parent, David Montani, Gérald Simonneau, Marc Humbert, Olivier Sitbon. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J, 50 (2) 1700889; 10.1183/13993003.00889-2017

Member's Comments

No comment yet.

Related content which might interest you: Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1800279; 10.1183/13993003.00279-2018 Year: 2018 Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1702606; 10.1183/13993003.02606-2017 Year: 2018 Risk assessment in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 390-398 Year: 2016 Risk stratification and medical therapy of pulmonary arterial hypertension Source: Eur Respir J, 53 (1) 1801889; 10.1183/13993003.01889-2018 Year: 2019 Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model Source: Eur Respir J, 50 (2) 1700740; 10.1183/13993003.00740-2017 Year: 2017 Early detection and management of pulmonary arterial hypertension Source: Eur Respir Rev 2012 21: 306-312 Year: 2012 Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model Source: Eur Respir J, 52 (4) 1800497; 10.1183/13993003.00497-2018 Year: 2018 Risk assessment, therapy and cardiovascular comorbidity in patients with pulmonary arterial hypertension Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020 The study of risk in pulmonary arterial hypertension Source: Eur Respir Rev 2012 21:234-238 Year: 2012 Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management Source: Eur Respir J, 53 (1) 1801916; 10.1183/13993003.01916-2018 Year: 2019 Pulmonary arterial hypertension: tailoring treatment to risk in the current era Source: Eur Respir Rev, 26 (146) 170095; 10.1183/16000617.0095-2017 Year: 2017 Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 53 (6) 1802004; 10.1183/13993003.02004-2018 Year: 2019 A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension Source: Eur Respir J, 56 (3) 2000513; 10.1183/13993003.00513-2020 Year: 2020 EmPHasis-10 is associated with clinical outcome measures in pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Risk stratification in pulmonary arterial hypertension (PAH) Source: International Congress 2018 – New trends in the management of pulmonary hypertension Year: 2018 Early improvements predict outcomes in pulmonary arterial hypertension Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Identification of treatment goals in paediatric pulmonary arterial hypertension Source: Eur Respir J 2014; 44: 1616-1626 Year: 2014 Treatment options for paediatric pulmonary arterial hypertension Source: Eur Respir Rev 2010 19: 321-330 Year: 2010 Pregnancy outcomes in pulmonary arterial hypertension in the modern management era Source: Eur Respir J 2012; 40: 1304-1305 Year: 2012